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PHeart Failure
-Type Natriuretic Peptide
trongly Reflects Diastolic Wall Stress
n Patients With Chronic Heart Failure
omparison Between Systolic and Diastolic Heart Failure
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uita and Kobe, Japan
OBJECTIVES We explored the stimulus for B-type natriuretic peptide (BNP) secretion in the clinical
setting of heart failure (HF).
BACKGROUND Increasingly, plasma BNP levels are being incorporated into the clinical assessment and
management of systolic heart failure (SHF) as well as diastolic heart failure (DHF). However,
heterogeneity in BNP levels among individuals with HF can cause some confusion in
interpreting results.
METHODS In 160 consecutive patients presenting with HF, we measured plasma BNP levels and
performed echocardiography and cardiac catheterization. Systolic and diastolic meridional
wall stress was calculated from echocardiographic and hemodynamic data.
RESULTS Although plasma BNP had a significant correlation (r2  0.296 [p  0.001]) with left
ventricular end-diastolic pressure (EDP) as previously reported, the correlation between
plasma BNP and end-diastolic wall stress (EDWS) (r2  0.887 [p  0.001]) was more
robust. In a subanalysis of 62 patients with DHF, a similar result was obtained (r2  0.143
for EDP and r2  0.704 for EDWS). In a comparison between SHF and DHF, the BNP
level was significantly higher in SHF (p  0.001). Although EDP did not show any
difference, EDWS was significantly higher in SHF than in DHF (p  0.001).
CONCLUSIONS The present study shows that plasma BNP levels reflect left ventricular EDWSmore than any
other parameter previously reported, not only in patients with SHF, but also in patients with
DHF. The relationship of left ventricular EDWS to plasma BNP may provide a better
fundamental understanding of the interindividual heterogeneity in BNP levels and their
clinical utility in the diagnosis and management of HF. (J Am Coll Cardiol 2006;47:742–8)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.11.030© 2006 by the American College of Cardiology Foundation
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hlasma B-type natriuretic peptide (BNP) levels are reported
ot only to be a strong marker of left ventricular (LV)
ysfunction, but also a marker to predict morbidity and
ortality accurately in patients with chronic heart failure
HF) (1,2). Recently, BNP-guided therapy for chronic HF
See page 749
as been suggested. Troughton et al. (3) demonstrated that
harmacotherapy guided by BNP levels reduces cardiovas-
ular events and delays time to first cardiovascular event
ompared with intensive clinically guided therapy. Recent
eports also demonstrated the contribution of LV diastolic
unction to plasma BNP levels and the usefulness of BNP in
he diagnosis of diastolic HF (4).
From the *Division of Cardiology, National Cardiovascular Center, Suita, Japan;
nd the †Department of Cardiovascular Medicine, Kobe City General Hospital,
obe, Japan. Dr. Iwanaga is presently affiliated with the Department of Cardiovascular
edicine, Kyoto University Graduate School of Medicine, Kyoto, Japan. This study was
upported by a research grant from Osaka Heart Club (Japan) and a grant for Clinical
ascular Function from Kimura-Kinenn Foundation (Japan).t
Manuscript received January 25, 2005; revised manuscript received July 13, 2005,
ccepted August 22, 2005.However, heterogeneity in BNP levels among individuals
ith HF has been recognized, and it has caused some
onfusion in interpreting results (5). Previous human studies
ave suggested correlations between BNP levels and cardiac
unctional or dimensional indexes such as end-diastolic
ressure (EDP), ejection fraction (EF), pulmonary capillary
edge pressure, and LV volume, none of which sufficiently
xplain the heterogeneity (6–9). Therefore, it is essential to
etermine the stimulus for BNP secretion in the clinical
etting of HF. In vitro studies have clarified the mechanism
f secretion and regulation of BNP precisely (10). Stretch of
ardiomyocytes is reported to be the most important stim-
lus of BNP regulation (11). It is also believed that BNP in
umans may be released from the heart in response to
ncreased wall stress. However, there have been few human
tudies exploring a direct relationship between wall stress
nd BNP regulation (12). Vanderheyden et al. (13) have
ery recently demonstrated, for the first time, in 40 patients
ith aortic stenosis (AS), a significant correlation of BNP
ith LV end-diastolic wall stress (EDWS). In their study,
owever, subjects were limited to patients with AS. Hence,
here now is a need for the same assessment in patients
w
s
p
d
M
P
C
D
w
w
d
A
c
f
p
c
a
B
E
a
L
C
c
t
m
u
E
p
2
l
u
D
q
m
p
m
m
t
e
w
W
P
w
v
(
u
a
i
p
743JACC Vol. 47, No. 4, 2006 Iwanaga et al.
February 21, 2006:742–8 BNP and LV Wall Stressith HF of various etiologies. Accordingly, in the present
tudy, we evaluated plasma BNP levels in 160 consecutive
atients presenting with HF of various etiologies including
iastolic HF.
ETHODS
atients. Among the patients referred to our National
ardiovascular Center Hospital between October 2003 and
ecember 2004, we included in this study those admitted
ith congestive heart failure (CHF) consecutively. Patients
ho did not undergo LV catheterization or had renal
ysfunction (serum creatinine 2.0 mg/dl) were excluded.
sample of 160 patients was obtained. For all participants,
ardiac catheterization and echocardiograms were per-
ormed at a compensated CHF stage (before discharge), and
lasma BNP was measured on the day before cardiac
atheterization. The clinical characteristics of these patients
re listed in Table 1.
Table 1. Patient Characteristics
Total
n 160
Women 31
Age, yrs 66.8  1.0
BMI, kg/m2 22.9  0.3
NYHA functional class 2 32
HT 71
DM 35
HLP 53
AF 18
Etiology
DCM 18
ISCM or OMI 29
HHD 26
VHD 26
Medications
ACEI or ARB 70
Beta-blocker 51
Diuretics 60
BNP, pg/ml 282  23
Values are mean  SEM or %.
ACEI  angiotensin-converting enzyme inhibitor; AF 
body mass index; DCM  dilated cardiomyopathy; DHF
Abbreviations and Acronyms
AS  aortic stenosis
BNP  B-type natriuretic peptide
CHF  congestive heart failure
DHF  diastolic heart failure
EDP  end-diastolic pressure
EDWS  end-diastolic wall stress
EF  ejection fraction
HF  heart failure
LV  left ventricle/ventricular
LVEDVI  left ventricular end-diastolic volume index
LVMI  left ventricular mass index
SHF  systolic heart failure
SWS  systolic wall stresshypertensive heart disease; HLP  hyperlipidemia; HT  hyperte
York Heart Association; OMI  old myocardial infarction; SHFNP assay. Blood was collected into tubes containing
DTA, and plasma BNP was measured using a validated
nd commercially available immunoassay kit (Tosoh Co.
td., Japan).
ardiac catheterization. Left ventricular pressure was re-
orded with a 5-F pigtail catheter connected to a fluid-filled
ransducer. Left ventricular volume and EF were deter-
ined with left ventriculography with contrast medium
sing Kennedy’s formula.
chocardiography. Echocardiographic examinations were
erformed with a Sonos 5500 machine equipped with a
.5-MHz probe. M-mode images were obtained to measure
eft atrial and ventricular dimensions (14). The left ventric-
lar mass index (LVMI) was estimated from the formula of
evereux et al. (15). The severity of mitral regurgitation was
uantified on a semicontinuous scale from none (0) to
oderately severe (3). In patients with sinus rhythm, the
ulsed Doppler transmitral flow velocity was recorded to
easure a ratio of peak mitral E-wave velocity to peak
itral A-wave velocity (E/A ratio) and the deceleration
ime of the mitral E-wave velocity.
On the basis of hemodynamic and echocardiographic data,
nd-diastolic and systolic meridional wall stresses (WS)
ere calculated. These were obtained by using the formula:
S  0.334  P(LVID)/WT(1  WT/LVID), where
 LV pressure (i.e., peak systolic pressure or EDP, which
as obtained during cardiac catheterization), LVID  left
entricular internal dimension, and WT  wall thickness
16). In the present study, the posterior wall thickness was
sed to assess WT regardless of regional wall motion
bnormalities. In the analysis of the interobserver reproduc-
bility of the posterior wall thickness measurement in 48
atients with CHF, a high degree of the reproducibility was
SHF DHF p Value
98 62
25 40 0.052
66.3  1.3 67.7  1.6 0.485
22.8  0.4 23.1  0.4 0.684
37 24 0.138
61 87 0.001
36 34 0.946
49 58 0.338
17 19 0.912
30 0
44 6
9 53
17 40
77 57 0.013
54 46 0.397
71 42 0.001
379  33 129  13 0.001
l fibrillation; ARB  angiotensin receptor blocker; BMI 
iastolic heart failure; DM  diabetes mellitus; HHD atria
 dnsion; ISCM  ischemic cardiomyopathy; NYHA  New
 systolic heart failure; VHD  valvular heart disease.
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BNP and LV Wall Stress February 21, 2006:742–8ound with an intraclass correlation coefficient value 0.830
95% confidence interval 0.609 to 0.925), and absolute
ifference was small (mean  SD; 0.01  1.16 mm). Also,
dequate M-mode images were not available in three
atients, and they were excluded in the present study.
tatistical analysis. Comparisons between groups were
ade using chi-square analysis for proportions and unpaired
tudent t tests for continuous variables. Linearity of a
elationship between two variables was assessed by linear
egression analysis; p  0.05 was considered significant.
esults were expressed as mean  SEM.
ESULTS
atient characteristics. Clinical characteristics of the
roup of 160 patients are summarized in Table 1. Mean age
as 66.8  1.0 years (range 20 to 87 years), and 31% of the
atients were women. In all, 98 patients had HF symptoms
ith an LV EF of 50%. These comprised the systolic
eart failure group (SHF). The diastolic heart failure group
DHF) was comprised of 62 patients with preserved systolic
unction (LV EF 50%). Mean age and body mass index
id not differ significantly between SHF and DHF groups,
hile there was a trend of more female patients in DHF. A
istory of hypertension and etiologies of dilated cardiomy-
pathy and ischemic cardiomyopathy/old myocardial infarc-
ion were more prevalent in SHF. Patients with SHF were
ore likely to be taking angiotensin-converting enzyme
nhibitors or angiotensin receptor blockers and diuretics.
Geometric and functional parameters obtained by echo-
ardiography or cardiac catheterization are shown in Table
. In total patients, mean EF was 41.5  1.1% (range 13%
o 66%), and mean LVMI and LV end-diastolic volume
ndex (LVEDVI) were 166  4 g/m2 and 106  4 ml/m2,
espectively.
orrelations of plasma BNP to echocardiographic and
emodynamic parameters. Scatter plots of plasma BNP
evels (dependent variable) against some echocardiographic
nd hemodynamic parameters (independent) are shown in
able 2. Echocardiographic and Hemodynamic Parameters
Total
(n  160)
SHF
(n  98)
DHF
(n  62) p Value
S, % 27  1 20  1 38  1 0.001
VEDD, mm 57  1 61  1 50  1 0.001
VMI, g/m2 166  4 179  5 145  6 0.001
AD, mm 45  1 45  1 44  1 0.779
/A 1.3  0.1 1.5  0.2 1.0  0.1 0.024
F, % 41.5  1.1 32.0  0.9 56.4  0.5 0.001
VEDVI, ml/m2 106  4 125  15 76  2 0.001
VSP, mm Hg 134  3 124  3 151  4 0.001
VEDP, mm Hg 14.9  0.4 15.0  0.6 14.8  0.5 0.829
alues are mean  SEM.
EF  ejection fraction; E/A  ratio of peak mitral E-wave velocity to peak mitral
-wave velocity; FS  fractional shortening; LAD  left atrial dimension;
VEDD  left ventricular end-diastolic dimension; LVEDP  left ventricular
nd-diastolic pressure; LVEDVI  left ventricular end-diastolic volume index;
VMI  left ventricular mass index; LVSP  left ventricular peak systolic pressure.
ther abbreviations as in Table 1.igure 1. There were strong correlations between LV EF, aVEDVI or LV end-systolic volume index, or LV EDP
nd plasma BNP (coefficient of correlation; r2  0.325,
.343, 0.421, and 0.328, respectively). There were weak
orrelations with parameters of transmitral Doppler flow
2  0.201 and 0.101 for E/A and deceleration time,
espectively. In contrast, LVMI and left atrial diameter did
ot show significant correlations with BNP levels. Although
V systolic wall stress (SWS) calculated by echocardio-
raphic and hemodynamic parameters showed a modest
orrelation (r2  0.277), a correlation of BNP with LV
DWS was much more robust (r2  0.887).
Although age, gender, and atrial fibrillation were not
ignificantly associated, body mass index (BMI) and New
ork Heart Association functional classII were associated
ith BNP levels (p  0.001 in both).
omparison between SHF and DHF. Plasma BNP levels
ere significantly higher in SHF than in DHF (median
interquartile range]; 267 [136 to 583] and 105 [64 to 146]
g/ml, respectively, p  0.001); however, EDP levels did
ot show any differences as shown in Figure 2 and Table 2.
ther parameters such as SWS, EDWS, LV end-diastolic
imension, LVMI, LVEDVI, and LV peak systolic pres-
ure were significantly higher in SHF than in DHF (p 
.001). Scatter plots in patients with SHF and DHF are
emonstrated in Figures 3A and 3B and Figures 3C and
D, respectively. End-diastolic wall stress showed a better
orrelation with BNP (r2  0.704) than EDP (r2  0.143)
n DHF as well as in SHF.
ubanalysis in patients without local wall motion abnor-
ality. It is conceivable that this estimation of wall stress
id not accurately reflect the entire non-uniform LV wall
tress in patients with regional asynergy in LV wall motion
r with variation in segmental LV wall thickness. In the
resent study, 83% of patients with ischemic cardiomyopa-
hy or old myocardial infarction and 28% with dilated
ardiomyopathy had regional wall motion abnormalities.
herefore, a subanalysis was performed for patients without
ocal wall motion abnormality (n  105). As a result, an
ven stronger correlation was obtained as shown (r2 
.919). A correlation in patients with regional wall motion
bnormality (n  55) was still strong (r2  0.820).
ISCUSSION
eterogeneity of BNP levels among individuals with HF
an cause some confusion in interpreting results. It has been
nclear why some patients with LV EF 35% have BNP
evels in the normal range whereas others exhibit extremely
levated levels, and why some patients with isolated diastolic
ysfunction (i.e., with normal EF) show a similar increase of
lasma BNP as do the patients with severe systolic dysfunc-
ion. One of the answers to the question has been the
hange of EDP levels in the LV (6). Another recent report
as demonstrated that heterogeneity of BNP levels in
atients with systolic HF reflects the severity of diastolic
bnormality, right ventricular function, and mitral regurgi-
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February 21, 2006:742–8 BNP and LV Wall Stressigure 1. Correlation between B-type natriuretic peptide (BNP) and left ventricular functional parameters in all 160 patients. (A) Left ventricular ejection
2raction (EF) (%). (B) End-diastolic pressure (EDP) (mm Hg). (C) End-systolic wall stress (SWS) (kdynes/cm ). (D) End-diastolic wall stress (EDWS)
kdynes/cm2).igure 2. Differences of B-type natriuretic peptide (BNP) and left ventricular functional parameters between systolic heart failure (SHF) (n  98) and
iastolic heart failure (DHF) (n  62). The box defines the interquartile range with the median indicated by the crossbar. The error bars indicate the 10th
2nd 90th percentiles. EDP  end-diastolic pressure (mm Hg); EDVI  end-diastolic volume index (ml/m ); EDWS  end-diastolic wall stress
kdynes/cm2); SWS  end-systolic wall stress (kdynes/cm2).
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BNP and LV Wall Stress February 21, 2006:742–8ation in addition to LV EF, age, and renal function (7).
he present study demonstrates the significance of LV
DWS in the regulation of BNP in patients with HF in
eneral. This was true not only in patients with SHF but
lso with DHF. Although correlation analysis suggested a
elationship between other parameters of LV geometry and
unction including EDP and plasma BNP levels, the corre-
ation between LV EDWS and BNP was the most robust
r2  0.887). Many studies including ours have shown that
NP levels correlate well with changes in filling pressures
uring tailored therapy (6,17), while O’Neill et al. (18)
ecently reported that plasma BNP might not correlate
losely with changes in intracardiac filling pressures. In any
ase, plasma BNP levels are not uniform across different
atients with the same LVEDP (i.e., interindividual heter-
geneity), and this may be because BNP is determined more
y EDWS than by filling pressure. Left ventricular EDWS
ight account for the wide variations that they observed in
atients with HF.
The present result suggests that LV EDWS may regulate
NP secretion in humans. Indeed, experiments using cul-
ured neonatal rat ventricular cells showed that cardiac
yocytes are able to respond to mechanical stretch by
ncreasing BNP secretion and gene expression (11). Wiese
igure 3. Correlation between B-type natriuretic peptide (BNP) and left v
A and B) and in 62 patients with diastolic heart failure (DHF) (C and D);
all stress (EDWS) (kdynes/cm2).t al. (19), using isolated human myocardium, have also Bemonstrated that, while the isometric contraction mode
id not have any influence on BNP expression, diastolic
verstretch increased BNP gene expression in a time-
ependent manner. This implies that diastolic stretch (i.e.,
reload rather than afterload) seems to be the mechanical
actor responsible for the induction of BNP expression and
ay be the reason that in the present study LV EDWS
hows a better correlation with the plasma BNP levels than
oes LV SWS. Furthermore, in vitro studies have impli-
ated the contributions of local paracrine and autocrine
actors in the stretch-induced BNP activation (11). Local
ngiotensin II was shown to play a critical role in the
evelopment of stretch-induced cardiac hypertrophy and to
t least partly regulate mechanical load-induced BNP ex-
ression. Recently, in addition to stimuli such as myocyte
tretching and neurohumoral activation, acute myocardial
ypoxia has been reported to increase cardiac BNP gene
ranscription and raise the plasma proBNP concentration in
n animal study (20). This mechanism may explain the
ncrease in plasma BNP in patients with acute coronary
yndromes and myocardial infarction (21). In the present
tudy, because such patients with acute ischemia were not
ncluded, the correlation between LV EDWS and plasma
ular functional parameters in 98 patients with systolic heart failure (SHF)
d C) end-diastolic pressure (EDP) (mm Hg) and (B and D) end-diastolicentric
(A anNP might actually be stronger.
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February 21, 2006:742–8 BNP and LV Wall StressMyocardial wall stress is one of the primary determinants
f myocardial oxygen consumption (22). Cardiac decom-
ensation is thought to result when the feedback loop that
ormalizes wall stress to abnormal loading of the heart
ysfunctions. The increased wall stress may act directly or
ndirectly via cellular mediators such as angiotensin, endo-
helin, inflammatory cytokines, reactive oxygen species, and
atrix metalloproteinase to orchestrate a variety of molec-
lar and cellular remodeling events determining the struc-
ural and functional properties of the myocardium and,
ltimately, the rate of disease progression (23–27). There-
ore, usefulness of plasma BNP levels in predicting morbid-
ty and mortality accurately in patients with chronic HF may
e explained by the relationship between the LV EDWS
nd BNP. Many other factors, such as age, gender, body
ass, genetics, etc., are also known to affect plasma BNP
evels. However, the demonstration of the link between the
emodynamics (LV EDWS) and neurohormonal factor
BNP) may support the usefulness of BNP-guided treat-
ent of HF. Although more randomized studies are
eeded, pharmacotherapy guided by BNP levels is intrigu-
ng and promising (3).
There are several methods to estimate the wall stress, and
e used a formula based on M-mode echocardiographic
ariables (16). This method may have several limitations.
or example, when there is regional asynergy in LV wall
otion and variation in local LV wall thickness, the
stimate may not reflect the entire non-uniform LV wall
tress correctly. To test this possibility, we analyzed the data
f the patients without LV asynergy demonstrated by
chocardiogram and LV ventriculography. We obtained an
ven better correlation. Interestingly, a correlation in pa-
ients with a local wall motion abnormality was still strong
r2  0.820). There are several other limitations to our
tudy. Echocardiography and blood sampling were typically
erformed the day before cardiac catheterization. This time
ag could have influenced the results. A further limitation is
hat the study population was composed of the patients who
ere in stable condition and could tolerate LV cardiac
atheterization; thus, patients who could not bear cardiac
atheterization (e.g., patients with New York Heart Asso-
iation functional class IV HF) were excluded.
In the present study, we demonstrated that plasma BNP
evels strongly reflect EDWS in the LV more than any other
arameter previously reported. In addition, EDWS accu-
ately accounts for the increase in plasma BNP levels even in
atients with diastolic HF. The relationship of LV EDWS
o plasma BNP may give a better understanding to the
nterindividual heterogeneity of plasma BNP levels and its
linical utility in the diagnosis and management of HF.
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epartment of Cardiovascular Medicine, Kyoto University Grad-
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